Repligen Corporation (NASDAQ: RGEN) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $10.4B. The Maz Rating grades it against the other companies in its sector.
Repligen Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $162.18, Repligen Corporation trades at 12.8x sales and 4.4x book value, with an EV/EBITDA of 82.1. Over the last twelve months it generated about $808M of revenue and a net loss of $13M. It runs a gross margin of 51.1%, an operating margin of 2.3% and a net margin of -1.5%. It shows return on equity of -0.6%, return on invested capital of -1.0% and a free cash flow yield of 1.0%. On the balance sheet: a debt-to-equity ratio of 0.33 and a current ratio of 9.88. Over the past 52 weeks the share price ranged from $100.99 to $198.87, with a beta of 1.12.
Repligen Corporation does not currently pay a dividend.
24 Wall Street analyst ratings cover the stock: 1 Strong Buy, 21 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.